Cynata Therapeutics has opened a fully underwritten $913,000 entitlement offer to fund adviser, director and consultant fees, offer costs and working capital. Eligible shareholders can buy three new shares for every eight held, with free options attached.
- $913,000 fully underwritten capital raising
- Three-for-eight entitlement at $0.01 per share
- One $0.02 option for every three new shares
- Offer closes on 27 October unless extended
- Proceeds allocated to fees, offer costs and working capital
Cynata launches $913,000 capital raising
Cynata Therapeutics Limited (ASX:CYP) has opened a fully underwritten entitlement offer targeting approximately $913,000 before costs, giving the biotech a defined near-term funding exercise but no new clinical or commercial milestone. The proceeds are earmarked for professional advisers, director and consultant fees, offer costs, strategic objectives and working capital.
The renounceable offer is priced at $0.01 a share and gives eligible shareholders the right to subscribe for three new shares for every eight held on 13 October. Caravel Securities is underwriting the offer, although the announcement does not disclose the underwriter fee or the company’s expected post-raising share count.
Free options add a second layer to the offer
For every three new shares subscribed, participants will receive one free attaching option. Each option carries a $0.02 exercise price and expires two and a half years after issue, creating a potential future source of capital if exercised, but one that is dependent on holders choosing to convert and the relevant conditions being met.
The offer follows Cynata’s 12 October replacement prospectus, which related to the same $913,000 raising. The current letter confirms that eligible holders are those with registered addresses in Australia, New Zealand or Singapore; holders elsewhere are excluded after the company considered the regulatory and compliance costs of extending the offer.
Funding timetable leaves a short decision window
Entitlement trading is scheduled to end on 20 October, while the offer is expected to close at 5pm AEDT on 27 October unless extended. Cynata expects to announce the result on 30 October and issue the new shares and attaching options on 3 November. Those dates make participation and underwriting outcomes the next immediate markers, while the stated use of proceeds leaves the longer-term funding position unresolved beyond this raising.
Bottom Line?
The underwriting provides structure to the $913,000 raise, but the next test is how much capital remains after fees and how long it can support Cynata’s stated objectives.
Questions in the middle?
- How much of the offer will be taken up by existing shareholders rather than the underwriter?
- What will Cynata’s post-offer share and option count be once the securities are issued?
- Will the funds provide sufficient working capital for the company’s next strategic step, or will further financing be required?